Chemotherapy-induced peripheral neuropathies: from clinical relevance to preclinical evidence.
about
Antibodies to the extracellular pore loop of TRPM8 act as antagonists of channel activationA polyamine-deficient diet prevents oxaliplatin-induced acute cold and mechanical hypersensitivity in ratsCentral pain processing in chronic chemotherapy-induced peripheral neuropathy: a functional magnetic resonance imaging studyChanges in ovarian function in premenopausal women with breast cancer undergoing adjuvant TC (docetaxel and cyclophosphamide) chemotherapy during a brief period of amenorrhea around the last chemotherapy cycle.Neurosteroid 3α-androstanediol efficiently counteracts paclitaxel-induced peripheral neuropathy and painful symptomsAnti-Neoplastic Cytotoxicity of Gemcitabine-(C4-amide)-[anti-EGFR] in Dual-combination with Epirubicin-(C3-amide)-[anti-HER2/neu] against Chemotherapeutic-Resistant Mammary Adenocarcinoma (SKBr-3) and the Complementary Effect of Mebendazole.Prevention of oxaliplatin-induced peripheral neuropathy by a polyamine-reduced diet-NEUROXAPOL: protocol of a prospective, randomised, controlled, single-blind and monocentric trial.Evidence that spinal astrocytes but not microglia contribute to the pathogenesis of Paclitaxel-induced painful neuropathyInfluence of Alternative Tubulin Inhibitors on the Potency of a Epirubicin-Immunochemotherapeutic Synthesized with an Ultra Violet Light-Activated Intermediate: Influence of incorporating an internal/integral disulfide bond structure and AlternativeGanglioside-monosialic acid (GM1) prevents oxaliplatin-induced peripheral neurotoxicity in patients with gastrointestinal tumors.After the chemotherapy: potential mechanisms for chemotherapy-induced delayed skeletal muscle dysfunction in survivors of acute lymphoblastic leukaemia in childhood.Sustained Accumulation of Microtubule-Binding Chemotherapy Drugs in the Peripheral Nervous System: Correlations with Time Course and Neurotoxic Severity.Potential Therapeutic Benefits of Maintaining Mitochondrial Health in Peripheral Neuropathies.Pathobiology of cancer chemotherapy-induced peripheral neuropathy (CIPN).Long-Term Effects, Pathophysiological Mechanisms, and Risk Factors of Chemotherapy-Induced Peripheral Neuropathies: A Comprehensive Literature Review.Monocytes expressing CX3CR1 orchestrate the development of vincristine-induced pain.Emerging trends in understanding chemotherapy-induced peripheral neuropathy.Chemotherapy-induced polyneuropathy: major agents and assessment by questionnaires.Minimizing chemotherapy-induced peripheral neuropathy: preclinical and clinical development of new perspectives.Incidence and risk of peripheral neuropathy with nab-paclitaxel in patients with cancer: a meta-analysis.Targeting AMPK for the Alleviation of Pathological Pain.Axonal Transport Impairment in Chemotherapy-Induced Peripheral NeuropathyPeripheral neuropathy induced by microtubule-targeted chemotherapies: insights into acute injury and long-term recovery.Mitochondrial Dysfunction in Chemotherapy-Induced Peripheral Neuropathy (CIPN).Inflammatory Response and Toxicity After Pressurized IntraPeritoneal Aerosol Chemotherapy.Long-term peripheral neuropathy symptoms in breast cancer survivors.Neuroprotective activities of curcumin and quercetin with potential relevance to mitochondrial dysfunction induced by oxaliplatin.Pain in cancer survivors.Sensory Neuronopathies
P2860
Q21131950-D8602271-B638-4E94-9D84-8DE208B30A2CQ28534748-57146CFD-EFF6-47BE-BF40-86F692CB9FF3Q33599361-E881E170-A116-42EF-92AF-3EB4F20A1E94Q33955356-B380FFEB-8EA6-48BB-A2F6-1A9C1C910EA2Q35049356-9432BD89-6A9A-4747-AFE5-A902863CA59FQ35237773-D5887251-FA91-4EFF-9812-0F6781189B3CQ35331858-F7ECB7EE-5F68-48CF-905B-BF9A4BE325C7Q35803293-4DF4804B-4ED1-4049-ADC8-4A222AEB5B1EQ35892045-FCF58D04-3502-4CEC-A9E6-68E5B9C63522Q36618130-F20A257A-DFA3-49A5-BAD4-C856E1AB8D15Q36778333-EEB343F9-4229-4609-BDB3-DE148DF0FF27Q36963585-DFF78342-AB3E-46C2-9D64-238F3F3C4E8BQ37168753-B280CF2C-AA33-4FB8-BBEF-4B5A6EA9F85FQ37399781-C7C942A1-192B-481B-83BD-6869EB3AE0F3Q37662576-034BECD1-C2DA-40CB-81D6-08E72148DDE8Q37726633-CFF344D2-F27C-407F-A679-F7E816E2D6E5Q38133440-86267EB0-E9F5-49D8-8C6E-B812880ABC75Q38209390-4418B573-77AE-4519-96D5-16D83C5B91A6Q38522262-FD184E63-24BC-4A52-8D1B-81B884C239EEQ38946259-264BA4A1-177F-4C27-B190-990C2903E844Q38998418-977ABA51-39AA-48A5-9293-B6C8B1E0888BQ42361415-04E73CE7-5AFD-49CE-B680-875A3C9D4946Q46235962-8B952527-1411-4A72-AD25-1DE5E35EA7B4Q46719997-1E45E747-CC03-4544-97F9-CEBEB6825B5FQ47109168-FCFEF778-1D75-48BE-BC37-ED53137863BEQ47265300-77CB8816-5857-4DAA-8546-0A2ACFD16498Q48155275-895DA108-A553-4BD3-A556-79BB6BC63B99Q54960570-E932A3D6-1739-4E03-BA37-1D21AD20FF16Q56501694-724EF168-1529-473E-A5C3-5B9F9783613F
P2860
Chemotherapy-induced peripheral neuropathies: from clinical relevance to preclinical evidence.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 06 January 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Chemotherapy-induced periphera ...... vance to preclinical evidence.
@en
Chemotherapy-induced periphera ...... vance to preclinical evidence.
@nl
type
label
Chemotherapy-induced periphera ...... vance to preclinical evidence.
@en
Chemotherapy-induced periphera ...... vance to preclinical evidence.
@nl
prefLabel
Chemotherapy-induced periphera ...... vance to preclinical evidence.
@en
Chemotherapy-induced periphera ...... vance to preclinical evidence.
@nl
P2093
P2860
P1476
Chemotherapy-induced periphera ...... vance to preclinical evidence.
@en
P2093
Alain Eschalier
David Balayssac
Denis Pezet
Juliette Descoeur
Nicolas Authier
P2860
P304
P356
10.1517/14740338.2011.543417
P407
P577
2011-01-06T00:00:00Z